*Segniliparus rugosus* is a rapidly growing acid-fast bacillus (AFB) that was isolated from human samples in 2005 \[[@bib1]\]. It has been identified as an emerging human pathogen that has been isolated from patients with and without cystic fibrosis (CF) \[[@bib2], [@bib3], [@bib4]\].

We describe the case of an 8-year-old child who was diagnosed with CF 2 years ago. The patient had the F508del/H609R mutations. Unlike many CF patients, he did not have a history of chronic *Pseudomonas aeruginosa* infections; however, *Staphylococcus aureus* and *Burkholderia cepacia* had previously been isolated from his sputum. Although AFB cultures yielded *Mycobacterium terrae* growth on one occasion (2018), he did not require treatment. *Aspergillus fumigatus* was isolated from this patient in 2016, 2017 and 2018. He was then diagnosed with allergic bronchopulmonary aspergillosis (ABPA) and was treated with corticosteroids and itraconazole.

On 8 November 2019, we received a sputum sample in our laboratory for bacteriological culture and testing for acid-fast staining. Because the sputum was 1+ AFB smear-positive, the sample was inoculated into Middlebrook 7H9 broth (Becton Dickinson, USA), using the Bactec MGIT 320 system (BD Diagnostics, USA), and Lowenstein--Jensen medium. On the fourth day of incubation, the Middlebrook broth was positive, and a subculture was performed on chocolate agar to test for rapidly growing non-tuberculosis bacteria (RGNTB). The bacteria grew on the chocolate agar at 35°C by the fourth day. Acid-fast staining tests of these colonies on the chocolate agar were positive. Therefore, we proceeded to perform PCR restriction fragment length polymorphism analysis (PRA) using the heat shock protein 65 (*hsp65*) gene \[[@bib5]\], and sequencing of the RNA polymerase subunit β (*rpoB)* gene \[[@bib6]\]. However, PCR of the *hsp65* gene did not produce amplicons, and *rpoB* gene sequencing identified *S. rotundus* with a low percentage identity (91.92%). We chose to sequence the 16S rRNA gene, which showed *S. rugosus* with 100% identity. Despite performing the recommended laboratory procedures, based on this AFB strain, the first molecular methods chosen were not appropriate in this case.

Antimicrobial susceptibility testing was performed using the Sensititre™ Rapid Myco (Thermo Scientific). The minimal inhibitory concentrations (MICs) were determined after incubation at 35°C for 4 days. The break points used for the RGNTB were determined according to the Clinical and Laboratory Standards Institute (CLSI) \[[@bib7]\]. The clinical *S. rugosus* (Z&Z215) isolate was susceptible to all the antibiotics tested ([Table 1](#tbl1){ref-type="table"}).Table 1Antimicrobial susceptibility patterns of *Segniliparus rugosus* (Z&Z215)Table 1AntibioticsMIC (μg/mL)Interpretation[a](#tbl1fna){ref-type="table-fn"}Trimethoprim/sulfamethoxazole\<0.25/4.75SCiprofloxacin\<0.12SMoxifloxacin\<0.25SCefoxitin\<4SAmikacin\<1SDoxycycline\<0.12STigecycline0.06SClarithromycin\<0.06SLinezolid\<1SImipenem\<2SCefepime\<1SAmoxicillin/clavulanic acid\<2/1SCeftriaxone\<4SMinocycline\<1STobramycin\<1S[^1][^2]

*S. rugosus* may be confused with RGMTB due to its acid-fast staining properties. In our case, only the sequencing analyses of the 16S rRNA genes allowed for the accurate identification of *S. rugosus*.

With the presence of AFB in the sputum of CF patients, the *Segniliparus* genus should be considered as a potential pathogen in additional to the classical bacteria such as *Nocardia*, *Actinomyces* and *Mycobacterium*. The identification of this genus continues to be a challenge for microbiology laboratories. We need to learn more about the importance and impact of *Segniliparus* in CF patients. This is the first reported case of *S. rugosus* in a patient with CF in Ecuador.
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[^1]: MIC, minimal inhibitory concentration; S, susceptible.

[^2]: According to the break points for rapid growth mycobacteria. Read on the 4th day of incubation.
